Sorafenib toluenesulfonate is a synthetic compound of sorafenib that targets growth signals and angiogenesis. Sorafenib blocks the enzyme RAF kinase, which is a key component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; In addition, sorafenib inhibits VEGFR-2/PDGFR- β Signal cascade, thereby blocking tumor angiogenesis.
*The following content is generated by AI and is for reference only.
Overview
Sorafenib toluenesulfonate is the tosylate salt form of Sorafenib, a multi-kinase inhibitor. It is synthesized via acid-base reaction between Sorafenib free base and p-toluenesulfonic acid to enhance stability and solubility for pharmaceutical manufacturing.
CAS No: 284769-51-3
Formula: C21H16F3N3O·C7H8O3S
Application
- Pharmaceutical Manufacturing: Primary API intermediate for oral oncology tablets targeting hepatocellular carcinoma and renal cell carcinoma.
- Formulation Development: Used in bioequivalence studies and generic drug production due to improved physical properties.
- Quality Control: Serves as reference standard for HPLC analysis in bulk drug substance verification.
Precautions
- Storage: Maintain in sealed containers at controlled room temperature (15-25°C) away from moisture.
- Safety: Handle with PPE; classified as potential reproductive toxin requiring strict industrial hygiene protocols.
- Usage: Restricted to licensed pharmaceutical facilities; not for direct clinical administration without formulation.